Speaker bio coming soon...

 

Robert Cobuzzi Jr., Ph.D. is Senior Vice President, Corporate Development of Endo Pharmaceuticals.  Dr. Cobuzzi joined Endo in 2005 with initial responsibility as Senior Director and then Vice President of Scientific Evaluation.  In 2008, he was named Acting Head of Corporate Development and was named Senior Vice President in 2010.  Before joining Endo, Dr. Cobuzzi was Director, Scientific Licensing at Adolor Corporation, which he joined in 2001.  From 1999 to 2001, Dr. Cobuzzi was in the regulatory affairs group at Centocor/Johnson & Johnson and prior to this position, he was part of the cardiovascular clinical team at AstraMerck from 1995 to 1999. 
Dr. Cobuzzi received his Ph.D. in molecular and cellular biochemistry from Loyola University Chicago, and a Bachelor of Arts degree in art history from Colby College.  

 

Chris joined AVI as President and Chief Executive Officer on January 1, 2011. He has served as a director of the Company since June 2010. Previously he was Vice President of Corporate Strategy for Celgene Corporation from July 2007. From November 2005 to June 2007, Chris served as an independent consultant to early stage biopharmaceutical companies. From 1997 to 1998 and from 1999 to November 2005, he worked at Gilead Sciences, Inc., where he served in a number of global leadership roles, including as Vice President of Corporate Development, Vice President of Marketing, and Vice President of Medical Affairs. Chris also held various commercial roles at COR Therapeutics, Inc. from 1998 to 1999 and at Abbott Laboratories from 1994 to 1997. He started his biopharmaceutical career as a consultant with Migliara/Kaplan Associates from 1991 to 1994. Chris received his BS in marketing from the University of Maryland.

 

Speaker bio coming soon...

 

Ellen Lubman is a Group Director in the Strategy, Alliances and Transactions Group at Bristol-Myers Squibb. Ellen focuses on M&A execution and strategy, identification of new transaction opportunities, and initiation of “String of Pearls� transactions, as well as spearheading novel business initiatives. Prior to joining Bristol-Myers Squibb, Ellen worked with Celtic Pharma, L.P., a private equity fund that acquires direct ownership or controlling stakes in commercially attractive pharmaceutical products in the late stages of clinical and regulatory development, and VIA Pharmaceuticals, a start-up cardiovascular disease biotechnology company incubated at Bay City Capital in San Francisco. During the heyday of the Human Genome Project, Ellen was a Biotechnology Equity Research Analyst at Robertson Stephens where she focused on Genomics, Proteomics, Drug Discovery and Technology Platform companies, and developed research pieces on Genetic Intellectual Property, Single Nucleotide Polymorphisms and other discovery technologies. Ellen holds a bachelor’s degree in Biological Sciences from Rutgers College and an MBA from the Stanford Graduate School of Business, including a Certificate in Global Management. She is a Director on the Board of Gilda's Club of NYC and the Investment Board of Springboard Enterprises.

 

Speaker bio coming soon...

 

Catherine Sazdanoff joined Takeda’s Global Business Development & Licensing group in December 2006, and became Vice President, Global Licensing in May 2008 after the Millennium acquisition.  She subsequently became VP, Corporate Development focusing on global M&A projects, and most recently was co-lead on the Nycomed acquisition in May 2011. 

In her new role as VP, Global Business Development, Catherine heads the team responsible for global R&D licensing and other strategic alliance transactions including M&A. 

Prior to Takeda, Catherine was employed by Abbott Laboratories, where she held a variety of business and law positions, including Director of Business Development for Abbott’s Pharmaceutical Products Division and Senior Counsel for International Transactions.  Other areas of responsibility at Abbott included managing commercial legal operations for Europe and Canada, global litigation, internal investigations, and commercial compliance.  Catherine was previously employed at the law firm of Isham, Lincoln & Beale in Chicago.

Catherine has a B.A. in English from the University of Notre Dame and a J.D. from Northwestern University School of Law.  She is Vice President of the Board of Directors of New York Pharma Forum and a member of Licensing Executives Society, Women Business Leaders, and American Bar Association.

 

Speaker bio coming soon...

 

Speaker bio coming soon...